GlobeImmune Recruiting for Clinical Trial
January 9, 2006
While GlobeImmune's therapeutic vaccine for Hepatitis C is only in Phase Ib of clinical trials, their focus on immunity to the Hepatitis C virus is fascinating. GI-5005 is based on tarmogens being potent activators of antigen-specific immune responses against disease.
Safety and Efficacy of the Therapeutic Vaccine GI-5005 Versus Placebo for the Treatment of Chronic Hepatitis C Infection
This study is currently recruiting patients.
Verified by GlobeImmune July 2005
Sponsored by: GlobeImmune
Information provided by: GlobeImmune
ClinicalTrials.gov Identifier: NCT00124215
Purpose:
The GI-5005 therapeutic vaccine or placebo will be injected under the skin of hepatitis C virus (HCV) subjects. Patients will be monitored for safety, immune responses and any therapeutic benefits related to the injections.
| Condition | Intervention | Phase |
| Hepatitis C | Vaccine: GI-5005 | Phase I |
MedlinePlus related topics: Hepatitis C
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Official Title: A Phase 1 Double-Blind, Placebo Controlled, Dose-Escalation, Multi-Center Therapeutic Trial of the Safety, Immunogenicity, and Efficacy of GI-5005; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing a Hepatitis C Virus NS3-Core Fusion Protein, in Patients With Chronic Hepatitis C Infection
Further study details as provided by GlobeImmune: GI-5005 targets two HCV antigens which are highly conserved, abundant and essential for virus replication. GI-5005 has demonstrated robust activity in preclinical models of HCV. Because the body’s response to Tarmogens resembles successful natural immunity to the hepatitis C virus, the Company believes that the GI-5005 Tarmogen may represent a successful approach to treating this difficult disease. The Company initiated a Phase 1b trial at five US centers for GI-5005 in July 2005.
Expected Total Enrollment: 48
Study start: June 2005
Eligibility:
Ages Eligible for Study: 18 Years and above
Genders Eligible for Study: Both Criteria
Inclusion Criteria:
• Patients with chronic hepatitis C virus infection including treatment naive subjects as well as subjects who are partial responders and relapsers to prior interferon therapy
• >18 years of age
• Negative skin test for hypersensitivity to saccharomyces cerevisiae.
Exclusion Criteria:
• Non-responders to previous interferon treatments
• Cirrhosis
• HCV treatment within 3 months
• Hepatitis B infection
• HIV infection
Location and Contact Information:
Please refer to this study by ClinicalTrials.gov identifier NCT00124215
John Ferraro 720-859-4134
California
Huntington Medical Research Institutes, Pasadena, California, 91105, United States; Recruiting
Ruth Co 626-397-5825
Myron Tong, M.D., Principal Investigator
Colorado
University of Colorado Health Sciences Center, Denver, Colorado, 80262, United States; Recruiting
Jennifer DeSanto 303-315-1128
Gregory Everson, M.D., Principal Investigator
Florida
University of Miami, Miami, Florida, 33136, United States; Recruiting
Angelique Brown 305-243-2184
Eugene Schiff, M.D., Principal Investigator
Illinois
University of Chicago, Chicago, Illinois, 60637, United States; Recruiting
Katie Wherity 773-702-4477
Helen Te, M.D., Principal Investigator
Donald Jensen, M.D., Sub-Investigator
New York
Weill Medical College of Cornell University, New York City, New York, 10021, United States; Recruiting
Mary Ahern 212-746-2115
Ira Jacobson, M.D., Principal Investigator
More Information:
Sponsor's website: http://www.globeimmune.com
Study ID Numbers: GI-5005-01
Last Updated: December 8, 2005
Record first received: July 25, 2005
ClinicalTrials.gov Identifier: NCT00124215
Health Authority: United States: Food and Drug Administration
Posted by Editors at January 9, 2006 2:23 PM
Site Topics
HCV Symptoms
You'll find links to a comprehensive symptoms list, as well as various studies and discussions about Hepatitis C symptoms.
Lab Tests
What they are and what they mean. Helps you interpret & understand all the various hepatitis lab tests likely to be encountered.
Hepatitis C Genotypes
Learn about Hepatitis C Genotypes and their variants.
Viral Load
Includes a convenient Viral Load chart, as well as a link to a detailed discussion on how to analyze and interpret viral load numbers.
What is...?
Learn more about various Hepatitis C related topics, including HCV, Ascites, Biopsies, and much more.
HCV Medicines
Numerous links to studies, info sheets, FAQs, and analysis of Ribavirin/Rebetron medicines.
Hepatitis C Doctors
A state-by-state and worldwide reference listing physicians who treat HCV, including an email link to submit your physician for inclusion.
Biopsy Info
A comprehensive resource of information relating to the liver biopsy.
Cirrhosis
Many discussions and analyses of cirrhosis, including causes, complications, pathology, symptoms, and much more.
Liver Cancer
Liver Cancer/Hepatocellular Carcinoma studies, info sheets, FAQs, and analysis.
Liver Disease Medicines
An exhaustive list of links to studies, info sheets, FAQs, and analysis of the various drugs used to treat liver disease.
Hep-Central Email List
Sign up to learn about advances and breakthroughs in Hepatitis C research, including information about medical and complementary treatments.
HCV Links
Convenient links to other sites external to Hepatitis-Central.
Mother/Child Transmission
Discussions of the special problems and precautions necessary involving mother to child transmission of Hepatitis C.
HCV Natural Remedies
A number of herbal products useful in the management of liver disease.
HCV Books
Recommended reading for those interested in hepatitis information.
Hepatitis C Forum
A Bulletin Board for discussions on hepatitis, treatments, etc.
Hepatitis C Activism
An easy way to get involved in urging our government to do more for Hepatitis C awareness and treatment research.
Advertisement
